Recent findings of the impact of new RSV prevention products aimed at protecting babies were published in the Morbidity and Mortality Weekly Report, an epidemiological digest prepared by the Centers ...

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...